Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma Review

   


Authors: Grommes, C.; Rubenstein, J. L.; DeAngelis, L. M.; Ferreri, A. J. M.; Batchelor, T. T.
Review Title: Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma
Abstract: Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain parenchyma, spinal cord, eyes, and cerebrospinal fluid without evidence of systemic, non-CNS involvement. PCNSL is uncommon and only a few randomized trials have been completed in the first-line setting. Over the past decades, the prognosis of PCNSL has improved, mainly due to the introduction and widespread use of high-dose methotrexate, which is now the backbone of all first-line treatment polychemotherapy regimens. Despite this progress, durable remission is recorded in only 50% of patients, and therapy can be associated with significant late neurotoxicity. Here, we overview the epidemiology, clinical presentation, staging evaluation, prognosis, and current up-to-date treatment of immunocompetent PCNSL patients. © The Author(s) 2018. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved.
Keywords: methotrexate; staging; diagnosis; therapy; pcnsl
Journal Title: Neuro-Oncology
Volume: 21
Issue: 3
ISSN: 1522-8517
Publisher: Oxford University Press  
Date Published: 2019-03-01
Start Page: 296
End Page: 305
Language: English
DOI: 10.1093/neuonc/noy192
PROVIDER: scopus
PMCID: PMC6380418
PUBMED: 30418592
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066963147&doi=10.1093%2fneuonc%2fnoy192&partnerID=40&md5=d56c0e16a86a49e367fe59b58035c96a
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Lisa De Angelis
    576 De Angelis
  2. Christian Grommes
    150 Grommes
Related MSK Work